SAR131675: Unveiling VEGFR-3 Inhibition in Advanced Cancer and Fibrosis Research

Introduction

Vascular endothelial growth factor receptor 3 (VEGFR-3) is pivotal in regulating lymphangiogenesis and angiogenesis, central processes in cancer progression, metastasis, and fibrotic disease. Targeting this receptor with high selectivity is a transformative approach in preclinical research on tumor biology and tissue remodeling. SAR131675, a selective and ATP-competitive VEGFR-3 inhibitor (SKU: B2301), stands out as a rigorously characterized tool compound, offering unmatched specificity for dissecting the VEGFR signaling pathway and its roles in pathophysiology. This article delivers a comprehensive scientific analysis, integrating advanced mechanistic perspectives and translational findings, with a focus on the expanding frontier of VEGFR-3 inhibition in cancer and fibrosis research.

VEGFR-3: A Central Node in Lymphangiogenesis, Angiogenesis, and Tumor Biology

VEGFR-3, primarily activated by VEGFC and VEGFD, orchestrates lymphatic endothelial cell survival, vessel formation, and immune cell trafficking. In cancer, the VEGFR signaling pathway is not only a driver of lymphangiogenesis and angiogenesis but also modulates the tumor microenvironment, impacting metastasis and immune cell recruitment. Dysregulation of this axis is increasingly implicated in chronic liver diseases, notably non-alcoholic steatohepatitis (NASH)-associated fibrosis, where VEGFC/VEGFR-3 signaling contributes to macrophage activation and tissue remodeling.

Mechanism of Action: SAR131675 as a Selective ATP-Competitive VEGFR-3 Inhibitor

Biochemical and Cellular Selectivity

SAR131675 is characterized by nanomolar potency against recombinant human VEGFR-3 kinase (IC₅₀ = 23 nM; K_i = 12 nM) and demonstrates ATP-competitive inhibition of VEGFR-3 autophosphorylation in HEK cells (IC₅₀ 30–50 nM). Critically, SAR131675 exhibits:

• High selectivity against VEGFR-1 (IC₅₀ > 3 μM) and VEGFR-2 (IC₅₀ = 235 nM), confirming its profile as a VEGFR-3 selective kinase inhibitor.
• Minimal or no activity across 65 kinases, 107 non-kinase enzymes and receptors, and 21 ion channels—making it an inhibitor with no off-target kinase, non-kinase enzyme, or ion channel activity.

Functionally, SAR131675 inhibits lymphatic endothelial cell survival induced by VEGFC (IC₅₀ = 14 nM) and VEGFD (IC₅₀ = 17 nM), as well as migration of human lung microvascular endothelial cells (HLMVEC) triggered by VEGFA (IC₅₀ = 100 nM) and VEGFC (< 30 nM).

Translational Impact: In Vivo Efficacy and Pathway Modulation

In preclinical mouse models, SAR131675 effectively abrogates lymphangiogenesis and angiogenesis (stimulated by FGF2), and exhibits antitumor efficacy by reducing tumor volume in 4T1 mammary carcinoma models. These results underscore its value as an anti-lymphangiogenic agent, anti-angiogenic compound, and tumor volume reduction agent in cancer research.

VEGFR-3 Inhibition in Advanced Cancer and Fibrosis Models: Beyond Conventional Usage

Dissecting the Tumor Angiogenesis Pathway and Microenvironment

While prior articles have emphasized SAR131675’s utility in standard lymphangiogenesis and cancer cell viability assays—for example, Optimizing Lymphangiogenesis Research with SAR131675 provides a workflow-oriented guide—this article extends the discussion to the multicellular consequences of VEGFR-3 pathway inhibition. Recent evidence indicates that SAR131675 not only restricts tumor lymphatic and blood vessel formation but also modulates immune cell infiltration and stromal remodeling, redefining its role as a tumor growth inhibition and inhibitor for tumor metastasis research.

VEGFR-3 Inhibition in Hepatic Fibrosis and Macrophage Polarization

A pivotal advance in the field is the elucidation of the hepatocyte-macrophage regulatory axis mediated by VEGFC/VEGFR-3, as highlighted in a recent seminal study (Li et al., Phytomedicine, 2026). In a high-fat diet (HFD)-induced NASH fibrosis model, SAR131675 administration led to:

• Downregulation of VEGFC and the chemokine CCL2/CCR2 axis
• Reduced infiltration of pro-inflammatory Ly6C^high monocytes
• Promotion of Ly6C^high-to-Ly6C^low macrophage transition (anti-fibrotic phenotype)
• Amelioration of hepatic inflammation and fibrosis

This work provides direct evidence that VEGFR-3 inhibitor for lymphangiogenesis research and angiogenesis pathway inhibitor compounds like SAR131675 can be leveraged to interrogate the immune-vascular crosstalk in chronic liver disease, extending their application far beyond classical cancer models.

Comparative Analysis: SAR131675 Versus Alternative VEGFR Pathway Inhibitors

In contrast to broader or less selective kinase inhibitors, SAR131675’s nanomolar potency and exquisite selectivity ensure minimal off-target activity and reduce confounding variables in mechanistic studies. While other VEGFR inhibitors may also target VEGFR-1 or VEGFR-2—or display significant cross-reactivity—SAR131675 remains a gold-standard VEGFR-3 selective kinase inhibitor and VEGFR-1 and VEGFR-2 low activity inhibitor. Its lack of activity against other kinases and non-kinase targets positions it as an ideal cancer biology research compound and preclinical drug candidate for pathway-focused investigations.

In relation to recent reviews such as SAR131675: Selective ATP-Competitive VEGFR-3 Inhibitor for Preclinical Research, which summarize the compound’s selectivity and application breadth, this article offers deeper analysis of downstream immunological and fibrotic mechanisms, leveraging the latest findings from hepatic fibrosis and tumor microenvironment models.

Advanced Applications of SAR131675 in Cancer and Fibrosis Research

Modeling the VEGFR Signaling Pathway in Complex Disease Contexts

SAR131675’s cell permeability and robust selectivity profile make it uniquely suited for advanced models of disease. In addition to standard in vitro migration and survival assays, researchers are now employing SAR131675 to:

• Dissect the interplay between lymphatic endothelial cell survival inhibition and immune cell dynamics in the tumor microenvironment
• Probe the contribution of VEGFC-induced lymphatic cell survival and VEGFD-induced lymphatic cell survival to metastatic dissemination
• Model the impact of VEGFA-induced endothelial cell migration inhibition on tumor vascularization and tissue remodeling
• Investigate the modulation of inflammatory and fibrotic signaling cascades in hepatic fibrosis and NASH

Translational Insights: From Tumor Models to Hepatic Fibrosis

The translational significance of SAR131675 is underscored by its role as a VEGFR-3 inhibitor for angiogenesis studies and antitumor agent in preclinical cancer models. Notably, its use in the aforementioned study (Li et al., Phytomedicine, 2026) demonstrates that VEGFR-3 inhibition can disrupt the pathological VEGFC-mediated signaling between hepatocytes and macrophages, offering a new therapeutic strategy for metabolic and fibrotic liver diseases. This extends the translational repertoire of SAR131675 from oncology to metabolic disease, setting a precedent for dual-disease modeling.

Whereas prior thought-leadership pieces, such as Precision Targeting of VEGFR-3: Strategic Guidance for Translational Research, have emphasized strategic applications and practical guidance, this article goes further by synthesizing new mechanistic discoveries, highlighting the intersection of vascular, immune, and fibrotic pathways enabled by highly selective VEGFR-3 inhibition.

Practical Considerations: Handling, Storage, and Limitations

SAR131675 is supplied as a solid and is recommended for storage at -20°C. The compound is insoluble in DMSO, ethanol, and water, and solutions are not suitable for long-term storage—critical factors for experimental planning. Despite its promising preclinical efficacy, SAR131675’s development as a therapeutic agent was discontinued due to adverse metabolic effects observed in animal models. This underlines its designation as a preclinical VEGFR-3 inhibitor and a powerful, yet research-limited, tool for mechanistic studies rather than clinical translation.

Researchers seeking highly selective ATP-competitive VEGFR-3 inhibitors for pathway analysis and disease modeling can obtain SAR131675 from APExBIO for use in advanced cancer, fibrosis, and immunology research contexts.

Conclusion and Future Outlook

SAR131675 exemplifies the next generation of VEGFR-3 autophosphorylation inhibitor compounds—combining nanomolar potency, high selectivity, and minimal off-target activity. Its evolving applications span from rigorous dissection of the lymphangiogenesis pathway and tumor angiogenesis pathway to uncovering novel mechanisms in metabolic and fibrotic disease models. By enabling researchers to unravel the complex interplay between vascular, immune, and stromal cells, SAR131675 continues to illuminate the VEGFR signaling pathway and its disease relevance.

While its development as a drug candidate was halted due to metabolic liabilities, SAR131675 remains an indispensable resource for preclinical research, setting the stage for new discoveries at the interface of cancer biology, immunology, and fibrosis. For investigators aiming to push the boundaries of VEGFR signaling pathway inhibitor research, SAR131675 offers a uniquely selective and mechanistically insightful platform to dissect disease processes and validate therapeutic hypotheses.